The paper summarises the present knowledge of the role of autoantibodies in the diagnosis of rheumatoid arthritis. The starting point were the current rheumatoid arthritis classification criteria. The first part presents the diagnostic features of rheumatoid factor and anti-citrullinated protein/peptide antibodies, while the second part provides the answers to the essential clinical questions related to their use. This article, as opposed to more comprehensive papers in the field of immunology, focuses on daily rheumatological practice. 
INTRODUCTION
Rheumatoid arthritis (RA) is the most common systemic connective tissue disease, which leads to progressive joint damage and the development of organ lesions. The objective of RA treatment is to cause the remission of the disease before any irreversible changes occur, which requires an early RA diagnosis and the administration of disease-modifying antirheumatic drugs. Given a heterogeneous clinical picture and an insidious onset of RA, meeting the aforementioned requirements poses a challenge [1, 2] .
Laboratory tests provide support for making clinical decisions in rheumatology. They make it possible to evaluate the activity of and diagnose numerous diseases; sometimes, they are of prognostic or predictive importance. Even though laboratory diagnostics has been developing, the basic methods still include complete blood count, inflammatory and biochemical markers, and urynalysis. Serological tests constitute a valuable auxiliary tool: but only in the hands of a well-prepared physician. Otherwise, they become a source of confusion, unnecessary expenses and patients' anxiety. It should be emphasised that the mere detection of autoantibodies does not determine the disease diagnosis and the selection of tests should closely correspond to a clinical hypothesis [3, 4] .
The objective of the paper is to summarise the present knowledge on the role of serological markers in the diagnosis of RA. Due to space limitations, the prognostic and predictive properties of autoantibodies were not analysed. Those will be discussed in another review.
RHEUMATOID FACTOR (RF)
The oldest serological marker of RA is rheumatoid factor (RF), i.e. a heterogeneous group of autoantibodies against the Fc portion of human immunoglobulin G [5] . Although the RF group includes all isotypes, only RF IgM has been widely used [6] . Therefore, it is RF IgM that will be discussed in this paper. Up to 2010, RF had been the only autoantibody that was considered in the classification criteria for RA [7] . In the advanced stage of the disease, its diagnostic sensitivity is 85%. The remaining 15% of cases concern the so-called seronegative RA, though this term is becoming less relevant in the light of new discoveries of autoantibodies [8, 9] . RF synthesis may precede the symptoms of RA by as many as 11 years, while the percentage of RF-positive results are estimated at 19-57% in the preclinical period [10] [11] [12] [13] . In these cases, the median period between the detection of seroconversion and the disease onset is between 2-4 years [11] [12] [13] . In very early RA, i.e. within less than 3 months after the onset of symptoms, the RF-positive result is found in 45% of patients [14] . Even up to 3 years from the disease onset the diagnostic sensitivity of the marker does not exceed 63% [15] . Treatment decisions that are made at the beginning of the disease condition the further course of the disease and the effectiveness of treatment; therefore, the role of RF as a marker of RA is very limited [2] . Another limitation of RF is its diagnostic specificity, which is low and depends greatly on the subject population. The diagnostic specificity ranges widely from 31 to 99%, which reflects a common and heterogeneous presence of RF in rheumatic, infectious, neoplastic and other diseases [16] . RF-positive results are also found in healthy people, with the incidence increasing with age. Table 1 summarises the occurrence of RF in different clinical groups.
ANTI-CITRULLINATED PROTEIN/PEPTIDE ANTIBODIES (ACPAS)
Anti-citrullinated protein/peptide antibodies (ACPA) are a newer marker of RA.
Citrullination is a post-translational modification of proteins or peptides, in which arginine residues are deiminated to citrulline residues (Fig. 1) . The peptidylarginine deiminase (PAD), which catalyses citrullination, is located inside various cells. For PAD to be activated, the concentration of Ca 2+ ions has to increase 100 times. Through the inflow of Ca 2+ ions from the extracellular space and their outflow from intracellular stores, such shifts take place during apoptosis and necrosis. A sudden death of a large number of cells hinders the phagocytosis of their fragments. As a result, PAD may be activated and proteins or peptides rich in arginine may be citrullinated. This scenario has been observed in various inflamed tissues -regardless of the triggering factor. Since the presence of citrullinated proteins is common, the specificity of ACPA for RA is not caused by citrullination itself, but by the tendency of patients to produce autoantibodies against citrullinated proteins. This tendency is considered to be the outcome of individual genetic and environmental factors [23] . Of course, the production of ACPA or other autoantibodies is not enough for the disease to develop. The majority of persons who produce autoantibodies do not suffer from the diseases related to them [24] . ACPA are usually determined using immunoenzymatic assays with cyclic citrullinated peptides as an antigen (Fig. 2) . Due to numerous and well-exposed citrulline residues, these synthetic molecules make it possible to capture ACPA from the test sample. The term "anti-cyclic citrullinated peptide autoantibodies" (anti-CCP) is derived from the laboratory assay. However, it should be noted that the CCP antigen is not present in vivo and the assays based on it are used to determine all ACPA in a test sample collectively. These antibodies detect specific citrullinated proteins or peptides but they may demonstrate a various degree of cross-reactivity. Consequently, every patient with a positive anti-CCP result has a very own set of ACPA antigenic specificities, which is referred to as an ACPA profile [26, 27] . The list of citrullinated antigens with a possible role in the pathogenesis of RA continues to expand. Better known citrullinated antigens include fibrin, vimentin, fibronectin, alpha- . According to present knowledge, the ACPA response "matures" in terms of antigenic specificity and isotype usage at the preclinical phase and stabilizes after RA onset [28] [29] [30] . In other words, ACPA profiles of particular RA patients are relatively conservative. A certain analogy with antinuclear antibodies (ANA) inspired the hypothesis that the ACPA profile may provide information of significant clinical importance. Therefore, its advocates compared the anti-CCP test to the detection of ANA by immunofluorescence, as well as the determination of particular ACPA to the ANA profile [31] . Even though research has been conducted for several years, there is still no evidence that the knowledge of an individual ACPA profile has any clinical benefits [32, 33] .
As already mentioned, the anti-CCP assay makes it possible to determine all ACPA in a test sample collectively and, as such, is a measure of the severity of the autoimmune response to citrullinated antigens. The diagnostic sensitivity of anti-CCP autoantibodies is 72%, which, to be exact, amounts to 75% in the advanced RA stage and 62% in the early RA stage. The boundary between these stages was established arbitrarily and was usually 12-24 months from the onset of symptoms. In very early RA, anti-CCP antibodies are present in only 41% of patients [14] . The main advantage of anti-CCP autoantibodies is a high diagnostic specificity, which is 99% for healthy persons and 94% for patients with rheumatic diseases other than RA [34, 35] . This means that the percentage of anti-CCP-positive results in healthy persons is 1%, while it is slightly higher -6% -for patients with diseases that "resemble" RA. Table 2 summarises the distribution of anti-CPP-positive results in va- In these cases, the median period between the detection of seroconversion and the disease onset is between 3-5 years [11-13].
Apart from the anti-CCP assay, there are also assays to determine autoantibodies against specific citrullinated proteins. There were high hopes for antibodies against citrullinated vimentin -Sa autoantigen [31] . The first Polish study -and the only one so far -did not reveal any benefits associated with the inclusion of anti-Sa autoantibodies in the diagnosis of RA [55] . The prognostic and predictive properties of this marker remain separate issues.
CLASSIFICATION CRITERIA FOR RA
In 2010, thanks to the joint effort by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), new classification criteria for RA were announced [7] . They replaced 23-years-old American classification criteria, which demonstrated a lower sensitivity in the early stage of the disease. One may say that the current classification algorithm focuses on such features of early undifferentiated arthritis that predispose patients to develop full-blown RA. The criteria are based on four variables named categories (Table 3) . They include the number and size of involved joints, the results of serological markers, the results of acute-phase reactants and the duration of symptoms. The document concerns two serological markers -RF and ACPA; however, neither is distinguished over the other. Values of autoantibodies are considered in relation to the upper limit of normal (ULN) for the laboratory and assay. The negative result refers to values that are less than or equal to the ULN; the low-positive result refers to values that are higher than the ULN but three or less times the ULN; and the high-positive result denotes values that are more than three times the ULN. If a qualitative assay was used to assess RF, every positive result is considered a low-positive result. The authors did not take a stand on the assay that should be used to assess ACPA but pointed out that the anti-CCP assay is typically used. It should be noted that autoantibodies are the second highest scoring category following joint involvement.
WHAT PERCENTAGE OF ANTI-CCP-POSITIVE INDIVIDUALS ACTUALLY SUFFER FROM RA?
The answer is a positive predictive value of the assay, which amounts to 93-97%. Unfortunately, as already mentioned, the positive anti-CCP results are not observed in 1/3 patients with RA [56] .
RF AND ACPA -SHOULD THEY BE TESTED COLLECTIVELY OR SHOULD EITHER OF THEM BE SELECTED?
According to the 2010 ACR/EULAR criteria, it is sufficient to test one of the mentioned autoantibodies, while both markers are Table 3 . 2010 classification criteria for RA acc. to the ACR/EULAR [7] Prerequisite: definite clinical synovitis in at least one joint (swelling) -with the synovitis not better explained by another disease. Differential diagnosis remain the responsibility of the physician.
The score of categories A-D should be added together. A total of at least 6 is needed for classification of a patient as having definite RA.
Patients with longstanding disease (irrespective of activity or treatment) and patients with typical erosions are classified as having definite RA if they have previously fulfilled the 2010 criteria based on retrospectively available data.
A. Number and size of the involved joints: On the other hand, in new draft guidelines being prepared by the National Institute for Health and Care Excellence (NICE), there is a direct indication that RF should be determined first and when the result is negative, the determination of anti-CCP should be considered. However, it was stressed that it is necessary to assess anti-CCP in all patients with newly diagnosed RA. This results from the prognostic and predictive properties of this marker, which are irrelevant in terms of the diagnosis itself, but crucial when it comes to further patient's care [57] . Given the current data and specific Polish conditions, it is beneficial to assess both RF and anti-CCP in patients with clinically suspected RA. If it is necessary to choose either of them, it is probably better to start with RF as it has a higher diagnostic sensitivity and its price is lower. However, the diagnosis of RA makes it obligatory to determine anti-CCP immediately.
RF AND ACPA -SHOULD THEY BE REPEATED IF THE RESULT IS NEGATIVE?
While on the subject of the RA diagnosis, we in fact refer to patients with undifferentiated arthritis. In this group, the percentage of anti-CCP-negative results with subsequent seroconversion to a positive value is 1.3-8.9%, while the percentage of seroconversion among RF-negative results is 1.9-10.0%. These observations were conducted for up to 5 years. The aforementioned data result from a different look at both markers -irrespective of their coexistence. Meanwhile, it was proven that the risk factor of the change from the RF-negative result to a positive one is the initial presence of anti-CCP, while the risk factor of the change from the anti-CCP-negative result to a positive one is the initial presence of RF. Perhaps that is why in the double-seronegative group, which is a true diagnostic issue, the percentage of seroconversion to anti-CCP-positive results is only 1.5% and it is 6.7% to RF-positive results. According to present scientific knowledge, the routine reassessment of RF or anti-CCP status is not justified in patients with undifferentiated arthritis with negative RF and/or anti-CCP results [58, 59] .
DOES THE GENERATION OF THE ANTI-CCP ASSAY MATTER?
Depending on the structure of CCP used, three generations of assays to measure anti--CCP autoantibodies are distinguished. In the first generation, CCP1 molecules were derived from human filaggrin. The second generation features more complex and synthetic CCP2 molecules. These molecules were designed by combining millions of peptides with sera from RA patients, which revealed epitopes of significant clinical importance. As a result, the diagnostic sensitivity of the marker was increased without affecting its specificity. The latest assay -the third generation -includes CCP3 peptides, which have been obtained with the use of combinatorial biochemistry to achieve a better exposure of epitopes. The majority of papers have not confirmed the superiority of the CCP3 assay over the CCP2 assay as yet. The CCP2 assay is still the most frequently used and best documented technique to measure ACPA; therefore, all data cited in this paper concern the second-generation assay [60] [61] [62] .
MAY THE IMPACT OF THE LABORATORY OR THE PRODUCER OF THE ASSAY ON THE ANTI-CCP RESULT BE SIGNIFICANT?
Even though the standardisation of anti--CCP determination is definitely better than that of RF, the results achieved in different assays or laboratories may vary significantly. The main factors that affect the results of serological assays include the general analytical technique (its type and automation degree), the composition and quality of the reagents, the structure and properties of the binding antigen, physical conditions of the surroundings, the assumed value of the ULN and the correctness of the test performance. There are documented cases in which the diagnostic concordance of two different CCP2 assays was only 60% [23, 62, 63] .
IS THE HIGH-POSITIVE ANTI-CCP RESULT PATHOGNOMONIC FOR RA?
A higher value of anti-CCP reduces the risk of a false positive result but does not eliminate it entirely. High-positive results were observed in the course of various diseases, which included e.g. tuberculosis, autoimmune hepatitis or spondyloarthropathies. Their significance is still unclear [19, 48, 64] . This is the main reason why serological tests should be administered individually, based on the medical history and physical examination, and why positive results of such tests -even if they are very high -are not pathognomonic for RA. From the rheumatological point of view, the patient does not suffer from laboratory test results but from a disease -defined as a specific clinical picture.
CONCLUSIONS
Serological markers are a valuable tool to support a differential diagnosis of arthritis, including, most of all, rheumatoid arthritis. The awareness of their basic qualities and, at the same time, numerous limitations may not only facilitate and accelerate a proper diagnosis of RA, but also decrease the overdiagnosis of this disease. Both aspects have a profound impact on the safety and quality of life of our patients. 
WPROWADZENIE
Reumatoidalne zapalenie stawów (RZS) jest najczęstszą układową chorobą tkanki łącznej, prowadzącą do postępującego uszkodzenia stawów i rozwoju zmian narządowych. Celem leczenia RZS jest osiągnięcie remisji jeszcze przed wystąpieniem nieodwracalnych zmian, co wymaga wczesnego rozpoznania choroby i włączenia leków modyfikujących jej przebieg. Z uwagi na heterogenny obraz kliniczny i podstępny początek RZS spełnienie tych warunków bywa wyzwaniem [1, 2] .
Wsparciem w podejmowaniu decyzji klinicznych w reumatologii są badania laboratoryjne. Ułatwiają one rozpoznanie i ocenę aktywności wielu chorób, a niekiedy mają znaczenie prognostyczne lub predykcyjne. Mimo rozwoju diagnostyki laboratoryjnej, podstawą pozostają: morfologia krwi, wskaźniki zapalne i biochemiczne oraz badanie ogólne moczu. Testy serologiczne są cennym narzędziem pomocniczym -ale tylko w rękach dobrze przygotowanego lekarza. W przeciwnym razie stają się źródłem nieporozumień, zbędnych wydatków i niepokoju pacjentów. Należy podkreślić, że samo wykrycie autoprzeciwciał nigdy nie przesądza o rozpoznaniu, a dobór badań powinien ściśle odpowiadać hipotezie klinicznej [3, 4] .
Celem pracy było podsumowanie aktualnej wiedzy na temat roli markerów serologicznych w rozpoznawaniu RZS. Z uwagi na ograniczoną objętość tekstu, nie omawiano właściwości prognostycznych i predykcyjnych autoprzeciwciał. Będą one tematem przyszłe-go opracowania.
CZYNNIK REUMATOIDALNY (RF)
Najstarszym serologicznym markerem RZS jest czynnik reumatoidalny (RF, rheumatoid factor), czyli heterogenna grupa auto-przeciwciał przeciw fragmentowi Fc ludzkich immunoglobulin klasy G [5] . Rodzina RF obejmuje wszystkie izotypy, lecz szerokie zastosowanie znalazł tylko RF IgM i to jemu poświę-cono poniższe rozważania [6] . Do 2010 roku RF był jedynym autoprzeciwciałem uwzględ-nianym w kryteriach klasyfikacyjnych RZS [7] . Jego czułość diagnostyczna w zaawansowanym okresie choroby wynosi 85%. W pozostałych 15% przypadków mówi się o tak zwanej postaci seronegatywnej, choć pojęcie to -w świetle nowych odkryć autoprzeciwciał -traci obecnie na znaczeniu [8, 9] . Synteza RF może poprzedzać objawy RZS nawet o 11 lat, a odsetek wyników RF-pozytywnych w okresie przedklinicznym ocenia się na 19-57% [10-13]. W tych przypadkach mediana czasu między stwierdzeniem serokonwersji a zachorowaniem wynosi od 2 do 4 lat [11-13]. W bardzo wczesnym okresie RZS, czyli poniżej 3 miesięcy od początku objawów, wynik RF-pozytywny stwierdza się u 45% chorych [14] . Jeszcze do 3 lat od zachorowania czułość diagnostyczna markera nie przekracza 63% [15] . Decyzje terapeutyczne podejmowane na początku choroby warunkują jej dalszy przebieg i skuteczność leczenia, stąd rola RF jako markera RZS jest mocno ograniczona [2] . Drugim ograniczeniem jest jego niska i wybitnie zależna od populacji badanej swoistość diagnostyczna. Parametr ten waha się w szerokim zakresie 31-99%, co oddaje powszechną, a zarazem zróżnicowaną, obecność RF w chorobach reumatycznych, infekcyjnych, nowotworowych i innych [16] . Wyniki RF-pozytywne stwierdza się także u osób zdrowych, a częstość tego zjawiska rośnie z wiekiem. Występowanie RF w różnych grupach klinicznych podsumowano w tabeli 1.
AUToPRZECIwCIAŁA PRZECIw CYTRUlINowANYM BIAŁKoM lUB PEPTYdoM (ACPA)
Nowszym markerem RZS są autoprzeciwciała przeciw cytrulinowanym białkom lub peptydom (ACPA, anti-citrullinated protein/peptide antibodies). Cytrulinacja jest modyfikacją posttranslacyjną białek lub peptydów, polegająca na deiminacji reszt argininy z wytworzeniem reszt cytruliny (ryc. 1). Katalizują-cy ją enzym, deiminaza peptydyloargininowa (PAD, peptidylarginine deiminase), znajduje się we wnętrzu rozmaitych komórek. Aktywacja PAD wymaga 100-krotnego wzrostu stężenia jonów Ca
2+
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